+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 85Years
All Genders
ID06023186

Study of Mavacamten Treatment Effects on Heart Blood Flow in Adults with Obstructive Hypertrophic Cardiomyopathy Over 12 Months

Led by Michael Ayers · Updated on 2024-11-06

20

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the impact of mavacamten treatment on blood flow in the heart muscle of adults with obstructive hypertrophic cardiomyopathy oHCM. The study aims to find out if taking mavacamten improves blood flow in the heart muscle over time. Participants are adults diagnosed with oHCM who have been prescribed mavacamten as part of their normal medical care. Participants will take mavacamten under the guidance of their treating physician according to standard care. The study involves one group of patients who will have two heart scans using Positron Emission Tomography and Computed Tomography PET-CT. The first scan is done before starting mavacamten, and the second scan is done after 12 months of treatment to observe any changes. During the study, participants will undergo PETCT scans before and after one year of mavacamten therapy. Researchers will measure changes in myocardial perfusion reserve, which reflects blood flow in the heart muscle. Participants must follow their treatment plan and attend scheduled visits for scans and assessments. The total involvement lasts about 12 months, with careful monitoring to ensure quality imaging and adherence to therapy.

CONDITIONS

Brief Title

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here